Hartmann, Kerstin
Schlombs, Kornelia
Laible, Mark
Gürtler, Claudia
Schmidt, Marcus
Sahin, Ugur
Lehr, Hans-Anton
Article History
Received: 4 September 2018
Accepted: 10 October 2018
First Online: 20 October 2018
Ethics approval and consent to participate
: The study consisted of 49 human FFPE invasive breast carcinoma samples. Thirteen cases were derived from the Institute of Molecular Gynecological Oncology, Mainz, Germany. The use of archived samples was approved by the ethics committee of the Landesärztekammer Rheinland-Pfalz (837.139.05 (4797)). Thirty one cases were obtained from PATH Biobank (Patientsʼ Tumour Bank of Hope), Munich, Germany [CitationRef removed]. Patients provided individual, written informed consent for the storage of samples and data, follow-up contact, and further use of samples and data for research purposes. The processes of PATH Biobank have been approved by the ethics committee of the medical faculty of the University of Bonn (255/06). Five additional cases were purchased from commercial vendors (Asterand Biosciences, Detroit, USA MI; Proteogenex, Culver City, USA CA).
: Not applicable.
: US is founder and CEO of BioNTech Diagnostics GmbH. KH, KS, ML and CG are employees of BioNTech Diagnostics GmbH. MS and HAL declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.